Direct the activities of the Coulter Translational Research Partnership Program at the University of Michigan. The Mission of this program is to translate biomedical innovations from faculty at the University of Michigan Medical School and the Department of Biomedical Engineering to commercialization. The Michigan Coulter Program is funded through a $20M endowment. Proceeds from the endowment support collaborative translational research projects that address unmet health care needs, and lead to new biomedical product concepts designed to improve the diagnosis and treatment of disease. Significant goals for this program include working to identify and fund promising translational research projects, improving the effectiveness of collaborations between biomedical engineers and clinicians, and facilitating business development efforts that lead to additional outside funding, licensing deals, and venture backed start-up companies.

• Founder of pharmaceutical and life sciences business development, strategy consulting, marketing services, medical communications and market research firm.• Support the early stage development and commercialization efforts of numerous life science and pharmaceutical/biotech companies.

RetroSense Therapeutics is a biopharmaceutical company developing a gene therapy to restore vision in patients who suffer from blindness due to certain retinal degenerative conditions.